Caladrius Biosciences Inc (CLBS) Expected to Announce Earnings of -$0.83 Per Share
Wall Street analysts forecast that Caladrius Biosciences Inc (NASDAQ:CLBS) will announce earnings of ($0.83) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Caladrius Biosciences’ earnings. Caladrius Biosciences posted earnings of ($0.73) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 13.7%. The firm is expected to announce its next earnings report after the market closes on Thursday, March 22nd.
On average, analysts expect that Caladrius Biosciences will report full-year earnings of $2.02 per share for the current fiscal year. For the next financial year, analysts expect that the company will report earnings of ($3.36) per share. Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Caladrius Biosciences.
A number of research firms have recently issued reports on CLBS. HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of Caladrius Biosciences in a report on Wednesday, March 14th. Zacks Investment Research downgraded Caladrius Biosciences from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th.
A hedge fund recently raised its stake in Caladrius Biosciences stock. Vanguard Group Inc. boosted its position in shares of Caladrius Biosciences Inc (NASDAQ:CLBS) by 2.8% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 155,380 shares of the biotechnology company’s stock after purchasing an additional 4,163 shares during the quarter. Vanguard Group Inc.’s holdings in Caladrius Biosciences were worth $723,000 at the end of the most recent reporting period. 5.75% of the stock is owned by institutional investors.
About Caladrius Biosciences
Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.